About Transgene
Transgene is a company based in Illkirch-graffenstaden (France) founded in 1979. It operates as a HealthTech. The company has 165 employees as of December 31, 2024. Transgene offers products and services including TG4050, TG4001, TG6050, and BT-001. Transgene operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Adaptive Biotechnologies, among others.
- Headquarter Illkirch-graffenstaden, France
- Employees 165 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Transgene Sa
-
Annual Revenue
$36.36 K (USD)-97.04as on Dec 31, 2024
-
Net Profit
$-35.29 M (USD)-52.15as on Dec 31, 2024
-
EBITDA
$-42.23 M (USD)-20.25as on Dec 31, 2024
-
Latest Funding Round
$22.65 M (USD), Debt – Conventional
Mar 18, 2019
- Investors
-
Employee Count
165
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Transgene
Transgene is a publicly listed company on the EURONEXT with ticker symbol TNG in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Transgene
Transgene offers a comprehensive portfolio of products and services, including TG4050, TG4001, TG6050, and BT-001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Individualized vaccine developed for cancer using AI technology.
Vaccine designed for cancer with shared antigen targets.
Vaccine created for cancer immunotherapy with specific targets.
Oncolytic virus engineered to attack cancer tumor cells.
Unlock access to complete
Unlock access to complete
Funding Insights of Transgene
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Conventional — $22.6M
-
First Round
First Round
(01 Jun 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2019 | Amount | Debt – Conventional - Transgene | Valuation |
investors |
|
| Nov, 2017 | Amount | Post-IPO - Transgene | Valuation |
investors |
|
| Mar, 2014 | Amount | Post-IPO - Transgene | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Transgene
Transgene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Natixis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-disciplinary global financial services provider
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Transgene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Transgene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Transgene Comparisons
Competitors of Transgene
Transgene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Adaptive Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Transgene
Frequently Asked Questions about Transgene
When was Transgene founded?
Transgene was founded in 1979 and raised its 1st funding round 31 years after it was founded.
Where is Transgene located?
Transgene is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
How many employees does Transgene have?
As of Dec 31, 2024, the latest employee count at Transgene is 165.
What is the annual revenue of Transgene?
Annual revenue of Transgene is $36.36K as on Dec 31, 2024.
What does Transgene do?
Immunotherapies targeting cancer are designed and developed by Transgene. Focus is placed on therapeutic vaccines and oncolytic viruses. Platforms like myvac and Invir.IO are utilized for personalized and advanced treatments. The healthcare sector, specifically cancer immunotherapy, is primarily served. Solutions are created through genetic engineering and artificial intelligence. Collaboration with international partners and multidisciplinary teams is maintained. Clinical trials and research updates are regularly published.
Who are the top competitors of Transgene?
Transgene's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Transgene offer?
Transgene offers TG4050, TG4001, TG6050, and BT-001.
Is Transgene publicly traded?
Yes, Transgene is publicly traded on EURONEXT under the ticker symbol TNG.
Who are Transgene's investors?
Transgene has 1 investor. Key investors include Natixis.
What is Transgene's ticker symbol?
The ticker symbol of Transgene is TNG on EURONEXT.